Cowen preso was very good. Messages:
- No sacred cows
- '113 in first line is amazing. The sales force really needs to be tuned up to compete because if they are good, Ariad will see immediate revenue impacts
- what PP will cut is the key. I sure hope he doesn't partner more or sell off another asset.
- no new programs beyond '788 as of yet. The science is past its prime but maybe the mutation prediction processes can live on in a newer therapeutic approach as in immunotherapy. IMO, that's why Denner sees a b/o in the works. Use the processes in others' sciences going forward. This IP doesn't help our pps, but does make the company attractive in a b/o.
- the results of the strategic review now moved beyond ASCO, though a few weeks ago, it was reversed. I think they want to see if the data moves the pps, opens up more options perhaps.
Paris is doing the smart things, exactly what I wrote to the company in May 2014, on 3 of his 5 point plan. Just nearly 2 years later. Won't stop a b/o now as the most likely outcome.
The BoD overpaid themselves and the CEO, they breached their fiduciary responsibilities, they doctored their records and coerced and bought off their accuser...I want THE TRUTH!!!
